BBA
ABBV icon

Braun-Bostich & Associates’s AbbVie ABBV Stock Holding History

Braun-Bostich & Associates’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$354K Buy
1,405
+29
+2% +$6.24K 0.2% 83
2026
Q1 		$299K Hold
1,376
– – 0.19% 89
2025
Q4 		$314K Buy
1,376
+7
+0.5% +$1.59K 0.19% 86
2025
Q3 		$317K Sell
1,369
-73
-5% -$14.9K 0.2% 84
2025
Q2 		$268K Sell
1,442
-1
-0.1% -$186 0.18% 91
2025
Q1 		$302K Sell
1,443
-53
-4% -$10.3K 0.22% 84
2024
Q4 		$266K Sell
1,496
-175
-10% -$32.2K 0.19% 85
2024
Q3 		$330K Sell
1,671
-93
-5% -$17.4K 0.23% 75
2024
Q2 		$303K Buy
1,764
+25
+1% +$4.14K 0.22% 78
2024
Q1 		$317K Sell
1,739
-322
-16% -$55.5K 0.27% 90
2023
Q4 		$319K Buy
+2,061
New +$300K 0.29% 90
2023
Q3 		– Sell
-2,115
Closed -$285K – 54
2023
Q2 		$285K Buy
2,115
+419
+25% +$61.4K 0.61% 56
2023
Q1 		$270K Buy
1,696
+393
+30% +$60.1K 0.64% 56
2022
Q4 		$211K Buy
+1,303
New +$200K 0.61% 57
2020
Q4 		– Sell
-2,417
Closed -$212K – 61
2020
Q3 		$212K Sell
2,417
-2,020
-46% -$190K 0.21% 87
2020
Q2 		$436K Buy
4,437
+43
+1% +$3.79K 0.43% 43
2020
Q1 		$323K Buy
4,394
+2,523
+135% +$215K 0.41% 56
2019
Q4 		$168K Buy
+1,871
New +$155K 0.17% 90
2019
Q3 		– Sell
-4,059
Closed -$295K – 85
2019
Q2 		$295K Sell
4,059
-1,873
-32% -$147K 0.31% 66
2019
Q1 		$478K Sell
5,932
-835
-12% -$68.3K 0.5% 53
2018
Q4 		$624K Buy
6,767
+5,795
+596% +$510K 0.66% 45
2018
Q3 		$92K Buy
972
+448
+85% +$42.5K 0.09% 148
2018
Q2 		$49K Hold
524
– – 0.05% 177
2018
Q1 		$50K Sell
524
-510
-49% -$56K 0.04% 174
2017
Q4 		$100K Buy
+1,034
New +$97.5K 0.08% 136

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Braun-Bostich & Associates's ABBV Position: Q2 2026 in Review

Braun-Bostich & Associates increased its AbbVie (ABBV) stake by 2.1% in Q2 2026, buying an estimated $6.24K and bringing the position to 1,405 shares worth $354K. The position accounts for 0.2% of the portfolio, ranked #83.

Braun-Bostich & Associates first reported a position in ABBV in Q4 2017 and has held it in 25 quarters since. The position peaked at $624K in Q4 2018. 4,193 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Braun-Bostich & Associates held 1,405 shares of AbbVie worth $354K as of Q2 2026.
  • Braun-Bostich & Associates bought 29 AbbVie shares in Q2 2026, an estimated $6.24K.
  • AbbVie made up 0.2% of Braun-Bostich & Associates's portfolio in Q2 2026, its #83 holding.
  • Braun-Bostich & Associates first reported a position in AbbVie in Q4 2017 and has held it in 25 quarters since.
  • Braun-Bostich & Associates's AbbVie position peaked at $624K in Q4 2018.
  • 4,193 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Braun-Bostich & Associates's 13F filing for Q2 2026, filed 24 Jul 2026.